Home  /  Resource Library  /  Relapses after Achieving EFS24 in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era

Relapses after Achieving EFS24 in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era

Study investigated risk of relapse and survival outcomes of DLBCL patients treated with rituximab.